1. Gupta, R.K., Relyveld, E.H., Lindblad, E.B., Bizzini, B., Ben-Efraim, S., and Gupta, C.K. (1993) Adjuvants–a balance between toxicity and adjuvanticity. Vaccine. 11, 293–306.
2. Food and Drug Administration (FDA) Washington D.C. (1996) Preliminary guidelines for the manufacture and evaluation of DNA vaccines. Rockville, MD: Food and Drug Administration, Center for Biologics Evaluation and Research. Docket 96N-0400.
3. Bussiere, J.L., Mc Cormick, G.C., and Green, J.D. (1995) In Vaccine design: the subunit and adjuvant approach (M.F. Powell and M.J. Newman, eds.), Plenum Press, New York, pp. 61–79.
4. Regnström, K., Ragnarsson, E.G.E., Rydell, N., Sjöholm, I., and Artursson, P. (2002) Tetanus antigen modulates the gene expression profile of aluminum phosphate adjuvant in spleen lymphocytes in vivo. Pharmacogenomics J.
2, 57–64.
5. Regnström, K., Ragnarsson, E.G.E., and Artursson, P. (2003) Gene expression after vaccination of mice with formulations of diphtheria- or tetanus toxoid and different adjuvants: arrays identify shared immune response genes and vaccine-specific genes in spleen lymphocytes. Vaccine. 21, 2307–2317.